Prothena targets rare protein-misfolding disease in late-stage study
Elan Corp. spinout Prothena Corp. will take an experimental drug aimed at a rare protein-misfolding disease into a late-stage clinical trial, the company said Tuesday.
Prothena (NASDAQ: PRTA), whose operations are largely based in South San Francisco, said it will focus its drug on amyloid light-chain amyloidosis, or AL amyloidosis, in what's expected to be a 230-patient, Phase III study.
In the disease, misfolded amyloid proteins are deposited in tissue, causing progressive organ damage, including…
Source: bizjournals.com Health Care:Hospitals headlines - Category: Hospital Management Authors: Ron Leuty Source Type: news
More News: Amyloidosis | Clinical Trials | Health | Health Management | Hospital Management | Hospitals | Study